The addition of empagliflozin to cells cultured in hyperglycaemia and oxidative stress caused a decrease in TGF-β1 levels, implying that the beneficial effect of empagliflozin was, in part, facilitated by the inhibition of TGF-β1 in this cell model of diabetic nephropathy. Here, TGFB1 is linked to diabetic kidney disease.